58 patents
Page 2 of 3
Utility
Salts and crystal forms of omecamtiv mecarbil
11 Oct 22
Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
Filed: 16 Aug 19
Utility
Polymorphs of 1-(2-((((TRANS)-3-FLUORO-1-(3-FLUOROPYRIDIN-2-YL)CYCLOBUTYL)METHYL)AMINO)PYRIMIDIN-5-YL)-1H-PYRROLE-3-CARBOXAMIDE
6 Oct 22
Bradley P. MORGAN, Matthew W. PETERSON
Filed: 26 Jun 20
Utility
Polymorphs of (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
6 Oct 22
Provided herein are polymorphs of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.
Norma TOM, Matthew PFEIFFER, Denise ANDERSEN, Qi GAO
Filed: 16 Jul 20
Utility
Cardiac Sarcomere Inhibitors
29 Sep 22
Bradley P. MORGAN, Chihyuan CHUANG, Luke W. ASHCRAFT, Justin HO, Alfredo GARCIA
Filed: 3 Mar 22
Utility
Heterocyclic Compounds and Their Uses
22 Sep 22
Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
Mingda BI, Robert KUEHL
Filed: 8 Jun 22
Utility
Bisamide Sarcomere Activating Compounds and Uses Thereof
8 Sep 22
Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
Filed: 15 Feb 22
Utility
Polymorphs of (R)-N-(5-(5-ISOPROPYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-2-METHYL-2H-TETRAZOLE-5-CARBOXAMIDE
1 Sep 22
Provided herein are polymorphs of (R)—N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazole-5-carboxamide, compositions thereof, methods of preparation thereof, and methods of their uses.
Norma TOM, Denise ANDERSEN
Filed: 16 Jul 20
Utility
Cardiac Sarcomere Inhibitor Oral Formulations
25 Aug 22
Provided herein are formulations comprising cardiac sarcomere inhibitor (R)-N-(5-(5-ethyl-1,2,4-oxadia-zol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, processes for making such formulations, and methods of treating various cardiac diseases and conditions with such formulations.
Chunsheng QIAO
Filed: 16 Jul 20
Utility
Cardiac sarcomere inhibitors
16 Aug 22
Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
Filed: 30 Aug 19
Utility
Heterocyclic compounds and their uses
12 Jul 22
Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
Mingda Bi, Robert Kuehl
Filed: 23 Sep 19
Utility
Methods of Treating Heart Failure by Administering Omecamtiv Mecarbil
16 Jun 22
Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
Narimon Honarpour, Fady Malik
Filed: 11 Nov 21
Utility
Polymorphs and Cocrystals of a Cardiac Troponin Activator
16 Jun 22
Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.
Stephanie AZALI, Mary CHAVES, Ron C. KELLY, Steven M. MENNEN, Darren L. REID, Osama SULEIMAN, Ashraf WILSILY, Mark WRIGHT
Filed: 12 Mar 20
Utility
Bisamide sarcomere activating compounds and uses thereof
22 Feb 22
Mikkel V. Debenedetto, Justin Malinowski, Joshua Payette, Antonio Romero, David St. Jean, Jr.
Filed: 27 Mar 20
Utility
Process for the preparation of an amino-pyrimidine and intermediates thereof
12 Oct 21
Provided herein is a novel process for the preparation of an amino-pyrimidine and salts thereof.
Matthew Peterson, Kevin Lu, Bradley Morgan, David Morgans, Tohru Fukuyama
Filed: 26 Dec 18
Utility
Cardiac Sarcomere Inhibitors
9 Sep 21
Bradley P. MORGAN, Mark VANDERWAL, Chihyuan CHUANG
Filed: 25 Jun 19
Utility
Cardiac Sarcomere Inhibitors
19 Aug 21
Bradley P. MORGAN, Chihyuan CHUANG
Filed: 25 Jun 19
Utility
Salts and Crystal Forms of Omecamtiv Mecarbil
22 Jul 21
Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
Filed: 16 Aug 19
Utility
Compounds, Compositions and Methods
1 Jul 21
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, JR.
Filed: 12 Mar 21
Utility
Cardiac Sarcomere Inhibitors
20 May 21
Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
Filed: 4 Sep 20
Utility
Compounds, compositions and methods
13 Apr 21
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Bradley Paul Morgan, Alex Muci, Pu-Ping Lu, Erica Anne Kraynack, Todd Tochimoto, David J. Morgans, Jr.
Filed: 2 Jul 19